title: Genetic variation in the JAK/STAT/SOCS signaling pathway influences breast cancer-specific mortality through interaction with cigarette smoking and use of aspirin/NSAIDs: the Breast Cancer Health Disparities Study.
abstract: The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway is involved in immune function and cell growth; genetic variation in this pathway could influence breast cancer risk. We examined 12 genes in the JAK/STAT/SOCS signaling pathway with breast cancer risk and mortality in an admixed population of Hispanic (2,111 cases, 2,597 controls) and non-Hispanic white (1,481 cases, 1,585 controls) women. Associations were assessed by Indigenous American (IA) ancestry. After adjustment for multiple comparisons, JAK1 (three of ten SNPs) and JAK2 (4 of 11 SNPs) interacted with body mass index (BMI) among pre-menopausal women, while STAT3 (four of five SNPs) interacted significantly with BMI among post-menopausal women to alter breast cancer risk. STAT6 rs3024979 and TYK2 rs280519 altered breast cancer-specific mortality among all women. Associations with breast cancer-specific mortality differed by IA ancestry; SOCS1 rs193779, STAT3 rs1026916, and STAT4 rs11685878 associations were limited to women with low IA ancestry, and associations with JAK1 rs2780890, rs2254002, and rs310245 and STAT1 rs11887698 were observed among women with high IA ancestry. JAK2 (5 of 11 SNPs), SOCS2 (one of three SNPs), and STAT4 (2 of 20 SNPs) interacted with cigarette smoking status to alter breast cancer-specific mortality. SOCS2 (one of three SNPs) and all STAT3, STAT5A, and STAT5B SNPs significantly interacted with use of aspirin/NSAIDs to alter breast cancer-specific mortality. Genetic variation in the JAK/STAT/SOCS pathway was associated with breast cancer-specific mortality. The proportion of SNPs within a gene that significantly interacted with lifestyle factors lends support for the observed associations.
authors.affiliation: Department of Medicine, University of Utah, 383 Colorow, Salt Lake City, UT, 84108, USA, marty.slattery@hsc.utah.edu.
authors.forename: Martha L
authors.initials: ML
authors.lastname: Slattery
authors.forename: Abbie
authors.initials: A
authors.lastname: Lundgreen
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Hines
authors.forename: Gabriela
authors.initials: G
authors.lastname: Torres-Mejia
authors.forename: Roger K
authors.initials: RK
authors.lastname: Wolff
authors.forename: Mariana C
authors.initials: MC
authors.lastname: Stern
authors.forename: Esther M
authors.initials: EM
authors.lastname: John
mesh_terms: D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001241:Aspirin / Q000009:adverse effects*; D014408:Biomarkers, Tumor / Q000235:genetics*; D001940:Breast / Q000187:drug effects / Q000378:metabolism; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000401:mortality*; D016022:Case-Control Studies; D004347:Drug Interactions; D005260:Female; D005500:Follow-Up Studies; D020022:Genetic Predisposition to Disease; D054625:Healthcare Disparities; D006630:Hispanic or Latino; D006801:Humans; D053613:Janus Kinase 1 / Q000235:genetics; D053614:Janus Kinase 2 / Q000235:genetics; D008875:Middle Aged; D009367:Neoplasm Staging; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D011379:Prognosis; D012307:Risk Factors; D050794:STAT1 Transcription Factor / Q000235:genetics; D015398:Signal Transduction; D012907:Smoking / Q000009:adverse effects*; D000071222:Suppressor of Cytokine Signaling 1 Protein; D050826:Suppressor of Cytokine Signaling Proteins / Q000235:genetics; D015996:Survival Rate; D044465:White People
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D014408:Biomarkers, Tumor; C108944:SOCS1 protein, human; D050794:STAT1 Transcription Factor; C494079:STAT1 protein, human; D000071222:Suppressor of Cytokine Signaling 1 Protein; D050826:Suppressor of Cytokine Signaling Proteins; C507904:JAK1 protein, human; C507924:JAK2 protein, human; D053613:Janus Kinase 1; D053614:Janus Kinase 2; D001241:Aspirin
references.citation: Immunol Rev. 2009 Mar;228(1):273-87
references.pmid: 19290934
references.citation: Semin Cell Dev Biol. 2008 Aug;19(4):401-6
references.pmid: 18723104
references.citation: Biochem Biophys Res Commun. 2009 Sep 18;387(2):342-7
references.pmid: 19595669
references.citation: J Am Diet Assoc. 1994 Jul;94(7):761-6
references.pmid: 8021418
references.citation: Cell Signal. 2012 Jan;24(1):151-61
references.pmid: 21907792
references.citation: Genetics. 2000 Jun;155(2):945-59
references.pmid: 10835412
references.citation: Carcinogenesis. 2014 Aug;35(8):1750-9
references.pmid: 24670917
references.citation: Cancer Causes Control. 2010 Apr;21(4):577-86
references.pmid: 20084545
references.citation: Mol Cell Endocrinol. 2014 Jan 25;382(1):603-611
references.pmid: 23827176
references.citation: Salud Publica Mex. 1998 Mar-Apr;40(2):133-40
references.pmid: 9617194
references.citation: Breast Cancer Res Treat. 2013 Jun;139(2):477-88
references.pmid: 23624818
references.citation: Heredity (Edinb). 2005 Sep;95(3):221-7
references.pmid: 16077740
references.citation: Biochem J. 2006 Jan 1;393(Pt 1):7-20
references.pmid: 16336196
references.citation: FASEB J. 2006 Oct;20(12):2093-101
references.pmid: 17012261
references.citation: Cancer Res. 2000 Jun 15;60(12):3290-8
references.pmid: 10866323
references.citation: Bioessays. 2001 Feb;23(2):161-9
references.pmid: 11169589
references.citation: Mol Cell Endocrinol. 2014 Jan 25;382(1):560-569
references.pmid: 23541951
references.citation: Mol Cell Biol. 2004 Jan;24(1):258-69
references.pmid: 14673160
references.citation: Am J Hum Genet. 2004 Apr;74(4):765-9
references.pmid: 14997420
references.citation: Breast Cancer Res Treat. 2007 Mar;102(1):85-101
references.pmid: 17080310
references.citation: Am J Clin Nutr. 2008 Apr;87(4):978-84
references.pmid: 18400722
references.citation: Am J Epidemiol. 2001 Sep 1;154(5):434-41
references.pmid: 11532785
references.citation: Cell Physiol Biochem. 2008;21(4):305-14
references.pmid: 18441519
references.citation: Mol Cell Endocrinol. 2014 Jan 25;382(1):612-615
references.pmid: 23562422
references.citation: Neoplasia. 2008 Mar;10(3):287-97
references.pmid: 18320073
references.citation: J Mol Med (Berl). 2004 Jan;82(1):12-20
references.pmid: 14557860
references.citation: Mol Cell Endocrinol. 2014 Jan 25;382(1):616-621
references.pmid: 23531638
references.citation: Int J Oncol. 2011 Aug;39(2):383-91
references.pmid: 21617857
references.citation: Semin Cell Dev Biol. 2008 Aug;19(4):394-400
references.pmid: 18708155
references.citation: Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2905-13
references.pmid: 16365008
references.citation: Int J Cancer. 2014 Feb 1;134(3):629-44
references.pmid: 23832257
references.citation: Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1143-52
references.pmid: 14652273
references.citation: Biochim Biophys Acta. 2013 Jun;1833(6):1463-75
references.pmid: 23434684
references.citation: Gut Microbes. 2010 Sep;1(5):316-324
references.pmid: 21327040
references.citation: Genome Biol. 2004;5(12):253
references.pmid: 15575979
references.citation: Carcinogenesis. 2012 Aug;33(8):1512-21
references.pmid: 22562547
references.citation: Curr Pharm Des. 2004;10(23):2839-50
references.pmid: 15379672
references.citation: Genetics. 2003 Aug;164(4):1567-87
references.pmid: 12930761